ArticleFrontiers in immunology2026
Disease-specific biomarker value of C-reactive protein and its composite indices in autoinflammatory diseases: an integrated study of multi-modal omics and population cohorts.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoinflammatory diseases (AIDs) are a heterogeneous group of innate immune-driven disorders whose prevalence is rising globally, yet the lack of disease-specific biomarkers continues to hamper accurate disease activity assessment, phenotype stratification, and risk evaluation. C-reactive protein (CRP) is one of the most widely used markers of systemic inflammation, yet its disease-specific expression, clinical correlations, network connectivity, and cellular origin across both adult and pediatric AIDs have not been systematically examined. Methods: We established a single-center retrospective cohort including 11 adult and pediatric AIDs and age matched healthy controls. Baseline CRP measurements were obtained before anti-inflammatory or immunosuppressive therapy. We performed multivariate regression and subgroup analyses to examine the associations of CRP and its composite indices, the CRP to lymphocyte ratio (CLR) and CRP to albumin ratio (CAR), with different AIDs. We integrated a public serum proteomic dataset to construct CRP centered protein interaction networks in macrophage activation syndrome. We also analyzed single cell CITE seq and spatial transcriptomic data from healthy human liver to determine the cellular origin of CRP. Results: Serum CRP levels showed a disease specific distribution across AIDs, with the highest levels in hyperinflammatory conditions such as AOSD and MAS. CRP correlated with fever, rash, and arthralgia in AOSD, but showed no association with mucosal or articular phenotypes in other diseases. Both CLR and CAR showed stronger associations with disease risk than CRP alone in regression models. Proteomic network analysis positioned CRP as a prominently connected node in the MAS inflammatory interactome. Single cell and spatial transcriptomic data confirmed hepatocytes as the exclusive source of CRP transcripts in healthy human liver. Conclusions: These findings indicate a positive association of CRP and its composite indices with AIDs, suggesting their potential as disease-specific biomarkers. Yet, given the single-center retrospective design and lack of external validation, further multi-center prospective studies are required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.